Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer

Trial Profile

Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2018

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 14 Mar 2018 New trial record
    • 10 Feb 2018 Results assessing genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells, presented at the 2018 Genitourinary Cancers Symposium.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top